Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and Vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1039-1049

  Pelosi, Giuseppe ^a,b,j   Rossi, Giulio ^c   Bianchi, Fabrizio ^d   Maisonneuve, Patrick ^a   Galetta, Domenico ^a   Sonzogni, Angelica ^a   Veronesi, Giulia ^a   Spaggiari, Lorenzo ^a,b   Papotti, Mauro ^e   Barbareschi, Mattia ^f   Graziano, Paolo ^g   Decensi, Andrea ^h   Cavazza, Alberto ⁱ   Viale, Giuseppe ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f SANTA CHIARA HOSPITAL   (Italy)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h GALLIERA HOSPITAL   (Italy)

ⁱ S MARIA NUOVA HOSPITAL   (Italy)

^j NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

Biopsy; Diagnosis; Immunohistochemistry; Morphology; NSCLC; Surgical specimens

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; VIMENTIN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CELL DIFFERENTIATION; FEMALE; GOLD STANDARD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TUMOR BIOPSY; YOLK SAC TUMOR;

EID: 79958106556     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318211dd16     Document Type: Article

References (48)

1. Travis W, Brambilla E, Muller-Hermelink H, et al. Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
2. Travis W, Colby T, Corrin B, et al. Hystological Typing of Lung and Pleural Tumours. Berlin, Heidelberg, New York: Springer Verlag, 1999.
3. Kerr K. Pulmonary adenocacarcinomas: classification and reporting. Histopathology 2009;54:12-27.
4. Edwards SL, Roberts C, McKean ME, et al. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000;53:537-540. (Pubitemid 30432112)
5. Vazquez MF, Koizumi JH, Henschke CI, et al. Reliability of cytologic diagnosis of early lung cancer. Cancer 2007;111:252-258. (Pubitemid 47301284)
6. Fraire A, Roggli V, Vollmer R, et al. Lung cancer heterogeneity. Prognostic implications. Cancer 1987;60:370-375. (Pubitemid 17098602)
7. Roggli VL, Vollmer RT, Greenberg SD, et al. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol 1985;16:569-579. (Pubitemid 15049631)
8. Cataluna JJ, Perpina M, Greses JV, et al. Cell type accuracy of bronchial biopsy specimens in primary lung cancer. Chest 1996;109:1199-1203. (Pubitemid 26145656)
9. Rossi G, Pelosi G, Graziano P, et al. A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol 2009;17:206-218.
10. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411-414.
11. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
12. Rosai J. Why microscopy will remain a cornerstone of surgical pathology. Lab Invest 2007;87:403-408. (Pubitemid 46633129)
13. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med 2008;132:384-396. (Pubitemid 351328813)
14. Beasley MB. Immunohistochemistry of pulmonary and pleural neoplasia. Arch Pathol Lab Med 2008;132:1062-1072. (Pubitemid 351955737)
15. Pardo J, Martinez-Penuela AM, Sola JJ, et al. Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol 2009;17:383-392.
16. Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004;122:884-893. (Pubitemid 39577356)
17. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010;5:442-447.
18. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010;5:436-441.
19. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25.
20. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:1805-1811.
21. Johansson L. Histopathologic classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol 2004;8: 259-267. (Pubitemid 39370567)
22. Pelosi G, Pasini F, Olsen Stenholm C, et al. p63 immunoreactivity in lung cancer. Yet another player in the development of squamous cell carcinomas? J Pathol 2002;198:100-109. (Pubitemid 34966213)
23. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 2001;25:363-372. (Pubitemid 32175139)
24. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26:767-773. (Pubitemid 34546942)
25. Pelosi G, Fraggetta F, Nappi O, et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth and tumor cell motility: a clinicopathological and immunohistochemical study of 31 cases. Am J Surg Pathol 2003;27:1203-1215. (Pubitemid 37040582)
26. Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2010; 18:103-120.
27. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007;15:415-420. (Pubitemid 350307847)
28. Ring BZ, Seitz RS, Beck RA, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol 2009;22:1032-1043.
29. Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009;37:178-183.
30. Wu M, Szporn AH, Zhang D, et al. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers. Diagn Cytopathol 2005;33:223-227. (Pubitemid 41368249)
31. Liu J, Farhood A. Immunostaining for thyroid transcription factor-1 on fine-needle aspiration specimens of lung tumors: a comparison of direct smears and cell block preparations. Cancer 2004;102:109-114. (Pubitemid 38489968)
32. Finley JL, Silverman JF, Dabbs DJ. Fine-needle aspiration cytology of pulmonary carcinosarcoma with immunocytochemical and ultrastructural observations. Diagn Cytopathol 1988;4:239-243.
33. Hummel P, Cangiarella JF, Cohen JM, et al. Transthoracic fine-needle aspiration biopsy of pulmonary spindle cell and mesenchymal lesions: a study of 61 cases. Cancer 2001;93:187-198. (Pubitemid 32552841)
34. Bianchi F, Hu J, Pelosi G, et al. Lung cancers detected by screening with spiral computed tomography have a malignant phenotype when analyzed by cDNA microarray. Clin Cancer Res 2004;10:6023-6028. (Pubitemid 39287506)
35. Bianchi F, Nuciforo P, Vecchi M, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007; 117:3436-3444. (Pubitemid 350096999)
36. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 2010;5:1315-1316.
37. Pelosi G, Sonzogni A, Viale G. The classification of lung carcinoma: time to change the morphology-based approach? Int J Surg Pathol 2010;18:161-172.
38. Wallace W. The challenge of classifying poorly differentiated tumours of the lung. Histopathology 2009;54:28-42.
39. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 2009;22:709-717.
40. Pelosi G, Petrella F, Sandri MT, et al. A primary pure yolk sac tumor of the lung exhibiting CDX-2 immunoreactivity and increased serum levels of alkaline phosphatase intestinal isoenzyme. Int J Surg Pathol 2006; 14:247-251. (Pubitemid 44449073)
41. Iwasaki T, Ohta M, Kawahara K. Pulmonary pleomorphic carcinoma: diagnosis using small biopsy specimens. J Thorac Oncol 2010;5:1492.
42. Kaira K, Horie Y, Ayabe E, et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010;5:460-465.
43. Ito K, Oizumi S, Fukumoto S, et al. Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer 2010;68:204-210.
44. Zafar N, Johns CD. Pleomorphic (sarcomatoid) carcinoma of lung - cytohistologic and immunohistochemical features. Diagn Cytopathol 2011;39:115-116.
45. Pelosi G, Scarpa A, Manzotti M, et al. K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 2004;17:538-546. (Pubitemid 38868420)
46. Leone A, Graziano P, Gasbarra R, et al. Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer 2011;128: 732-735.
47. Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 2009;125: 2479-2482.
48. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.